The BST Device Benefits

E-QURE's BST Device - Practical & Clinical Benefits

The BST Device intended use - treatment of chronic non-healing wounds such as:  

  • Diabetic Wounds
  • Vascular (Arterial or Venous) Leg Ulcers
  • Pressure (Decubitus) Wounds
  • Other Ulcers / Wounds, which are resistance to standard or more complex treatments

E-QURE's BST Device demonstrates Well-Established Practical & Clinical Benefits

The BST Device offers a proven non-invasive electrotherapy option for the acceleration of healing and rapid closure of chronic wounds.

  • The BST Device is clinically approved for hospitals, clinics and home care
  • The BST Device is used only for 90 minutes a day.
  • The BST Device is easily applied by the caregiver or patient.
  • The BST Device  facilitates complete closure of hard-to-heal wounds (which are resistant to standard or advanced wound care within the average period of 6 to 8 weeks1
  • The BST Device is the only clinical available electrotherapy which is based on a novel bioelectrical signal discovered in humans.
  • The BST Device  is the only clinical available electrotherapy with proven therapeutic effectiveness in a Randomized Placebo Controlled Trial – RCT2
  • The BST Device significantly reduces the hospitalization period and treatment costs of non-healing chronic wounds.

The BST Device triggers a wound healing process which has the following effects:

  • Wound Healing - Initiation and acceleration of the wound healing process.
  • Pain - Reduction of local pain.Tissue viability - Significant increase in:
  • Granulation -Regeneration of viable connective tissue.
  • Epithelialisation -Regeneration of viable epithelial tissue.   
  • Vascularisation (angiogenesis) - Regeneration of vital blood vessels.


  • Ricci, E., Afargan, M. The effect of stochastic electrical noise on hard-to-heal wounds. J Wound Care, 2010; 19 (3):96-103.  
  • Ohry, A., Goren, O. The effects of BST DEVICE electrostimulation on healing of pressure ulcers: results of a multi-center, double blind, 1. randomized, placebo controlled study. EWMA J 2007; 7: oral aBST Deviceract no. 66.

Contact Us

E-QURE Corp.

20 West 64th street - Suite 39G
New York, NY 10023

Office: +972-8-9167333
Fax: +972-8-9167331

linkedin facebook twitter